|
Children''s Mental Health: Surveillance of Mental Disorders Among Children in the United States (CDC MMWR Special Report)
|
Resource Development
|
CDC, HRSA, SAMHSA
|
NIMH
|
In 2012, The Centers for Disease Control and Prevention (CDC) initiated a special Morbidity and Mortality Weekly Report (MMWR) on child mental health surveillance. This report provides a comprehensive look at surveillance systems that collect data on mental health issues. The report summarizes information about ongoing federal surveillance systems that provide estimates of the prevalence of mental disorders and indicators of mental health among children living in the United States, and presents estimates of childhood mental disorders and indicators from these systems during 2005-2011.
|
|
Chronic Fatigue Syndrome Advisory Committee (CFSAC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, OS
|
OD/DPCPSI/ORWH, CSR, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIDCR, NIDDK, NIEHS, NIMH, NINDS, NINR, NLM
|
The Chronic Fatigue Syndrome Advisory Committee (CFSAC) provides advice and recommendations to the Secretary of Health and Human Services via the Assistant Secretary for Health of the U.S. Department of Health and Human Services on issues related to chronic fatigue syndrome (CFS). These include: 1) factors affecting access and care for persons with CFS; 2) the science and definition of CFS; and 3) broader public health, clinical, research and educational issues related to CFS.
|
|
Clinical and Translational Research Course for PhD Students
|
Training Initiative
|
FDA
|
CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDDK, NIGMS, NIMH
|
The Clinical and Translational Research Course for Ph.D. Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to Ph.D. role models, research resources, and potential career opportunities at the NIH.
|
|
Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
This Working Group discusses a range of issues relevant to the development of antiviral drugs for the treatment of influenza.
|
|
Clinical Islet Transplantation Consortium
|
Research Initiative
|
CMS, FDA
|
NIDDK, NIAID
|
"The Clinical Islet Transplantation (CIT) Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in people with type 1 diabetes.
Studies conducted by the CIT Consortium will focus on improving the safety and long-term success of methods for transplanting islets, the insulin-producing cells of the pancreas, in people whose own islets have been destroyed by the autoimmune process that characterizes type 1 diabetes. One clinical trial, in particular, is studying the efficacy of islet transplantation after kidney transplantation. Participants may include Medicare beneficiaries. This study was mandated in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. "
|
|
Clinical Studies in Fecal Incontinence Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD
|
The purpose of this committee was to plan a meeting to present the research world with information on the state of fecal incontinence research and generate discussion about how to move forward research that will improve treatment and outcomes in people with fecal incontinence.
|
|
Clinical Trials Working Group (CTWG) Steering Committee System
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies.
|
|
Clinical Utilization Plan for Anthrax Medical Countermeasure Use in a Mass Casualty Event (CUPAC) Medical Countermeasures Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC
|
Dr. Marion Danis is participating as a member of the Medical Countermeasures Work Group to provide clinical algorithms that will assist clinicians to evaluate, triage, diagnose and treat large number of patients presenting with symptoms of anthrax. It will also provide a clinical prioritization schema for the use of medical countermeasures specific to anthrax and outline unique critical care issues that may require special consideration.
|
|
Clinical Vocabulary and Standards Development for Quality Measures
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, OS
|
NLM
|
NLM is developing and assessing the feasibility of standards-based quality measures that will utilize Electronic Medical Record (EMR) data. In 2012, NLM developed a system for validating value sets used in Meaningful Use Stage 2 clinical quality measures.
|
|
ClinicalTrials.gov
|
Resource Development
|
FDA
|
NLM, CC, NCATS, NCCAM, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/OSP
|
ClinicalTrials.gov is an NLM-operated database containing summary protocol and results information from publicly and privately funded clinical research. As of January 2014, the database included protocol information on more than 160,000 studies conducted in 185 countries, and more than 11,000 summary results records. NLM originally collaborated with FDA on implementing Section 113 of the Food and Drug Administration Modernization Act. It is currently collaborating with FDA and other parts of NIH to implement the statutory requirements of Section 801 of the Food and Drug Administration Amendments Act of 2007.
|